These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 22263524)

  • 1. Advancements in high throughput biophysical technologies: applications for characterization and screening during early formulation development of monoclonal antibodies.
    Samra HS; He F
    Mol Pharm; 2012 Apr; 9(4):696-707. PubMed ID: 22263524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accelerated formulation development of monoclonal antibodies (mAbs) and mAb-based modalities: review of methods and tools.
    Razinkov VI; Treuheit MJ; Becker GW
    J Biomol Screen; 2015 Apr; 20(4):468-83. PubMed ID: 25576149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aggregates in monoclonal antibody manufacturing processes.
    Vázquez-Rey M; Lang DA
    Biotechnol Bioeng; 2011 Jul; 108(7):1494-508. PubMed ID: 21480193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-throughput screening and stability optimization of anti-streptavidin IgG1 and IgG2 formulations.
    Alekseychyk L; Su C; Becker GW; Treuheit MJ; Razinkov VI
    J Biomol Screen; 2014 Oct; 19(9):1290-301. PubMed ID: 25023322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody engineering and modification technologies.
    Filpula D
    Biomol Eng; 2007 Jun; 24(2):201-15. PubMed ID: 17466589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of High Throughput Screening Techniques to Predict Stability of Monoclonal Antibody Formulations During Early Stage Development.
    Goldberg DS; Lewus RA; Esfandiary R; Farkas DC; Mody N; Day KJ; Mallik P; Tracka MB; Sealey SK; Samra HS
    J Pharm Sci; 2017 Aug; 106(8):1971-1977. PubMed ID: 28456733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Formulation and manufacturability of biologics.
    Shire SJ
    Curr Opin Biotechnol; 2009 Dec; 20(6):708-14. PubMed ID: 19880308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implementation of advanced technologies in commercial monoclonal antibody production.
    Zhou JX; Tressel T; Yang X; Seewoester T
    Biotechnol J; 2008 Oct; 3(9-10):1185-200. PubMed ID: 18759247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systematic multitechnique approach for detection and characterization of reversible self-association during formulation development of therapeutic antibodies.
    Esfandiary R; Hayes DB; Parupudi A; Casas-Finet J; Bai S; Samra HS; Shah AU; Sathish HA
    J Pharm Sci; 2013 Sep; 102(9):3089-99. PubMed ID: 23794522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The rapid discovery of engineered antibodies.
    Wang M; He M
    IDrugs; 2007 Aug; 10(8):562-5. PubMed ID: 17665332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation of dual-variable-domain immunoglobulin molecules for dual-specific targeting.
    Gu J; Ghayur T
    Methods Enzymol; 2012; 502():25-41. PubMed ID: 22208980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in the production and downstream processing of antibodies.
    Chon JH; Zarbis-Papastoitsis G
    N Biotechnol; 2011 Sep; 28(5):458-63. PubMed ID: 21515428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein-excipient interactions: mechanisms and biophysical characterization applied to protein formulation development.
    Kamerzell TJ; Esfandiary R; Joshi SB; Middaugh CR; Volkin DB
    Adv Drug Deliv Rev; 2011 Oct; 63(13):1118-59. PubMed ID: 21855584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-Throughput Screening and Analysis of Charge Variants of Monoclonal Antibodies in Multiple Formulations.
    Alekseychyk L; Su C; Becker GW; Treuheit MJ; Razinkov VI
    SLAS Discov; 2017 Sep; 22(8):1044-1052. PubMed ID: 28570837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Applications of CE SDS gel in development of biopharmaceutical antibody-based products.
    Rustandi RR; Washabaugh MW; Wang Y
    Electrophoresis; 2008 Sep; 29(17):3612-20. PubMed ID: 18803223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High throughput screening of protein formulation stability: practical considerations.
    Capelle MA; Gurny R; Arvinte T
    Eur J Pharm Biopharm; 2007 Feb; 65(2):131-48. PubMed ID: 17107777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Technological progresses in monoclonal antibody production systems.
    Rodrigues ME; Costa AR; Henriques M; Azeredo J; Oliveira R
    Biotechnol Prog; 2010; 26(2):332-51. PubMed ID: 20043321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Formulation development of antibodies using robotic system and high-throughput laboratory (HTL).
    Zhao H; Graf O; Milovic N; Luan X; Bluemel M; Smolny M; Forrer K
    J Pharm Sci; 2010 May; 99(5):2279-94. PubMed ID: 20014026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved Fluorescence Methods for High-Throughput Protein Formulation Screening.
    Wei Y; Larson NR; Angalakurthi SK; Russell Middaugh C
    SLAS Technol; 2018 Dec; 23(6):516-528. PubMed ID: 29884102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteins behaving badly: emerging technologies in profiling biopharmaceutical aggregation.
    Hamrang Z; Rattray NJ; Pluen A
    Trends Biotechnol; 2013 Aug; 31(8):448-58. PubMed ID: 23769716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.